HistoSonics news

HistoSonics was chosen as a 2020 Red Herring Top 100 North America Winner. “What has excited me most is to see so many people forging niches in high-tech and cutting edge sectors,” added Alex Vieux, Red Herring’s publisher. “Some of the technical wizardry and first-rate business models showcased at the conference has been fantastic to learn about. We believe HistoSonics embodies the drive, skill and passion on which tech thrives. HistoSonics should be proud of i

HistoSonics announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy and liquefy tissue in the liver without incisions, ionizing radiation or heat.

“The Breakthrough Device Designation is a significant milestone for our company and validates ou

HistoSonics announced today that the first patient has been treated as part of the company’s #HOPE4LIVER Europe Trial, which was approved by German authorities earlier in the year.  The study is designed to evaluate the safety and efficacy of the HistoSonics’ platform technology, which uses the novel science of histotripsy and the mechanical properties of therapeutic focused ultrasound, to destroy unwanted tissue, including targeted primary and metastatic liver tumors,

HistoSonics announced today the treatment of the first patient in the #HOPE4LIVER US Study.  The investigational device study was approved by the FDA in the fourth quarter of 2020. The study is designed to evaluate the safety and efficacy of the company’s platform technology, which uses the novel science of histotripsy, a form of therapeutic focused ultrasound, to mechanically destroy targeted primary and metastatic liver tumors, without invasive incisions or needles enterin